Hacibekiroglu, IlhanKodaz, HilmiTurkmen, Esma2024-06-122024-06-1220151300-7467https://doi.org/10.5505/tjoncol.2015.1088https://hdl.handle.net/20.500.14551/18439Prostat cancer is the most common type of cancer in men. At the time of diagnosis, only 5% of prostat cancer patients have the disease in advanced stage. While the 5 year overall survival rate of the patients with locoregional disease is close to 100%, this ratio in patients with advanced disease decreases to 28%. Prostat cancer cells depend on androgens for development, proliferation and physiological function. The purpose of the standard hormone therapy is to keep testesteron levels in castrate levels. Androgen deprivation therapy (ADT) is the standard treatment approach in prostat cancer patients with advanced stage. Although this treatment possesses many clinical benefits, it has also side effects affecting many systems in the body. This article evaluated the types and mechanisms of action of ADT, the management of this treatment's side effects, and the controversial situations commonly encountered in daily oncology practice in the light of current literature.tr10.5505/tjoncol.2015.1088info:eu-repo/semantics/openAccessAndrogen Deprivation TherapyProstate CancerAndrogen-Deprivation TherapyRandomized-TrialsBilateral OrchiectomyEuropean OrganizationCyproterone-AcetateGoserelin AcetateAmerican-SocietyOpen-LabelPhase-IiiFollow-UpArticle3012533N/AWOS:0003621083000052-s2.0-84928593408Q4